Propanc Biopharma, Inc. current report, 06 July 2022

Full document

Propanc Biopharma, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Propanc Biopharma, Inc. on July 6, 2022, reporting events that occurred on May 18, 2022, and July 6, 2022. The Company is incorporated in Delaware with principal executive offices in Camberwell, Australia.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure amendments rather than financial performance.

Material Changes

  • Authorized Common Stock Increase: The Company's authorized common stock (par value $0.001 per share) was increased from 1,000,000,000 shares to 3,000,000,000 shares.
  • Preferred Stock: The number of authorized preferred shares remains unchanged at 1,500,005.
  • Total Authorized Shares: The total number of shares of all classes and series the Company is authorized to issue is now 4,001,500,005.
  • Approval Process: The amendment was approved by the Board of Directors on May 18, 2022, and by a majority of Voting Stockholders via written consent under Section 228 of the Delaware General Corporation Law.
  • Effective Date: The Certificate of Amendment was filed with the Delaware Secretary of State and became effective on July 6, 2022.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items related to operations. The primary purpose of this filing is to disclose the amendment to the Certificate of Incorporation.

Key Facts for Investor Verification

  • Verify the effective date of the Certificate of Amendment (July 6, 2022) in Delaware state records.
  • Confirm the new total authorized share count of 4,001,500,005 shares.
  • Review the Company's capitalization table to understand the impact of the increased common stock authorization on potential dilution.
  • Check subsequent filings for any issuance of shares against the newly authorized common stock.